AZD-0328

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H16N2O
Molecular Weight	216.2789
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C1C2=CC=CN=C2O[C@]13CN4CC[C@H]3CC4

InChI

InChIKey=OCKIPDMKGPYYJS-ZDUSSCGKSA-N

InChI=1S/C13H16N2O/c1-2-10-8-13(16-12(10)14-5-1)9-15-6-3-11(13)4-7-15/h1-2,5,11H,3-4,6-9H2/t13-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19615981 | https://clinicaltrials.gov/ct2/show/NCT00669903

AZD0328, a spirofuropyridine, is a selective alpha7 nicotinic receptor agonist. This drug participated in clinical trials phase II in patients with schizophrenia. However, studies were terminated because the drug didn’t meet the current target product profile. Besides AZD0328 has been studied in phase I for the treatment of Alzheimer's disease.

Originator

Approval Year

PubMed

Title	Date	PubMed
Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes.	2009 Oct 1	19615981
Discovery and development of α7 nicotinic acetylcholine receptor modulators.	2011 Dec 8	21919481

Patents

Sample Use Guides

In Vivo Use Guide

Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.

Route of Administration: Oral

Name

Type

Language

AZD-0328

Common Name

English

AZD 0328

Common Name

English

SPIRO(1-AZABICYCLO(2.2.2)OCTANE-3,2'(3'H)-FURO(2,3-B)PYRIDINE), (2'R)-

Systematic Name

English

AZD0328

Code

English

AZD 0328 [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

2B218X5QIY